Suppr超能文献

对于大多数符合Z0011标准的淋巴结阳性乳腺癌患者,可避免腋窝淋巴结清扫和淋巴结照射:一项对793例患者的前瞻性验证研究

Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers: A Prospective Validation Study of 793 Patients.

作者信息

Morrow Monica, Van Zee Kimberly J, Patil Sujata, Petruolo Oriana, Mamtani Anita, Barrio Andrea V, Capko Deborah, El-Tamer Mahmoud, Gemignani Mary L, Heerdt Alexandra S, Kirstein Laurie, Pilewskie Melissa, Plitas George, Sacchini Virgilio S, Sclafani Lisa M, Ho Alice, Cody Hiram S

机构信息

*Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY †Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY ‡Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA.

出版信息

Ann Surg. 2017 Sep;266(3):457-462. doi: 10.1097/SLA.0000000000002354.

Abstract

OBJECTIVE

To determine rates of axillary dissection (ALND) and nodal recurrence in patients eligible for ACOSOG Z0011.

BACKGROUND

Z0011 demonstrated that patients with cT1-2N0 breast cancers and 1 to 2 involved sentinel lymph nodes (SLNs) having breast-conserving therapy had no difference in locoregional recurrence or survival after SLN biopsy alone or ALND. The generalizability of the results and importance of nodal radiotherapy (RT) is unclear.

METHODS

Patients eligible for Z0011 had SLN biopsy alone. Prospectively defined indications for ALND were metastases in ≥3 SLNs or gross extracapsular extension. Axillary imaging was not routine. SLN and ALND groups and radiation fields were compared with chi-square and t tests. Cumulative incidence of recurrences was estimated with competing risk analysis.

RESULTS

From August 2010 to December 2016, 793 patients met Z0011 eligibility criteria and had SLN metastases. Among them, 130 (16%) had ALND; ALND did not vary based on age, estrogen receptor, progesterone receptor, or HER2 status. Five-year event-free survival after SLN alone was 93% with no isolated axillary recurrences. Cumulative 5-year rates of breast + nodal and nodal + distant recurrence were each 0.7%. In 484 SLN-only patients with known RT fields (103 prone, 280 supine tangent, 101 breast + nodes) and follow-up ≥12 months, the 5-year cumulative nodal recurrence rate was 1% and did not differ significantly by RT fields.

CONCLUSIONS

We confirm that even without preoperative axillary imaging or routine use of nodal RT, ALND can be avoided in a large majority of Z0011-eligible patients with excellent regional control. This approach has the potential to spare substantial numbers of women the morbidity of ALND.

摘要

目的

确定符合美国外科医师学会(ACOSOG)Z0011试验标准的患者腋窝淋巴结清扫术(ALND)的实施率及淋巴结复发率。

背景

Z0011试验表明,接受保乳治疗的cT1-2N0期乳腺癌且前哨淋巴结(SLN)有1至2枚转移的患者,仅行SLN活检或ALND后,其局部区域复发率或生存率无差异。结果的可推广性及淋巴结放疗(RT)的重要性尚不清楚。

方法

符合Z0011试验标准的患者仅行SLN活检。预先确定的ALND指征为≥3枚SLN有转移或肉眼可见的包膜外侵犯。腋窝成像并非常规检查。采用卡方检验和t检验比较SLN组、ALND组及放疗野。采用竞争风险分析估计复发的累积发生率。

结果

2010年8月至2016年12月,793例患者符合Z0011试验标准且有SLN转移。其中,130例(16%)接受了ALND;ALND的实施情况不因年龄、雌激素受体、孕激素受体或HER2状态而有所不同。仅行SLN活检后的5年无事件生存率为93%,无孤立性腋窝复发。乳腺+淋巴结及淋巴结+远处转移的5年累积复发率均为0.7%。在484例仅行SLN活检且已知放疗野(103例俯卧位、280例仰卧位切线野、101例乳腺+淋巴结)且随访≥12个月的患者中,5年累积淋巴结复发率为1%,且在不同放疗野之间无显著差异。

结论

我们证实,即使不进行术前腋窝成像或常规使用淋巴结放疗,对于大多数符合Z0011试验标准的患者,也可避免ALND,且局部区域控制良好。这种方法有可能使大量女性免受ALND带来的并发症困扰。

相似文献

引用本文的文献

6
Intraoperative spectroscopic evaluation of sentinel lymph nodes in breast cancer surgery.乳腺癌手术中前哨淋巴结的术中光谱评估。
Breast Cancer Res Treat. 2024 Aug;207(1):223-232. doi: 10.1007/s10549-024-07349-z. Epub 2024 May 20.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验